BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Australia's First Cu-67 SAR-Bombesin Prostate Cancer Trial Patient Treated

COMBAT, which derives from "Copper-67 SAR-Bombesin in metastatic castrate resistant prostate cancer (NCT05633160)1 is a dose escalation and co...

October 04, 2023 | News

Akeso and RemeGen Team Up for Gastric Cancer Therapy Study

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/0...

October 02, 2023 | News

Bionomics Reports Positive Phase 2b Results for BNC210 in Post-Traumatic Stress Disorder Trial

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. St...

September 29, 2023 | News

Hong Kong's Akeso Receives FDA IND Clearance for AK117 in MDS Combo with Azacitidine

The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States. Based on th...

September 29, 2023 | News

Mabwell Starts Phase Ib/II Trial for Nectin-4 ADC with PD-1 Inhibitor

The clinical trial (CTR20232677) is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of 9MW2821 in combination with ...

September 29, 2023 | News

OBiO Launches GMP Facility Intelli-M for Rapid Delivery of Innovative Therapies

The launch of the new base in Shanghai will enhance OBiO's production and service capabilities in both China and the United States...

September 28, 2023 | News

Kivo launches unified platform offering best-in-class collaboration and compliance solution

Kivo GO is a new, unified platform for emerging life sciences companies who need to manage documents and processes across their Regulatory, Clinical and ...

September 27, 2023 | News

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design

Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design...

September 27, 2023 | News

Ascletis Completes Enrollment for Glioblastoma Treatment Trial

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ...

September 27, 2023 | News

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

"We're thrilled to strengthen our existing suite of patents," said Peter Choo, Chairman of CytoMed. "Now this novel iPSC-based technology has been gra...

September 26, 2023 | News

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to disco...

September 22, 2023 | News

Asieris Pharmaceuticals' APL-1702 Achieves Key Milestone in Cervical HSIL Treatment Trial

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs fo...

September 21, 2023 | News

SomaLogic and Korea’s DNA Link Join Forces to Expand SomaScan® Platform in Asia-Pacific Proteomics Market

SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, announced its partnership with DNA Link, an innovator in personalized a...

September 20, 2023 | News

China's NMPA Recommends Priority Review for Cefepime-Taniborbactam in UTI Treatment

"Currently, the clinical challenges from multi-drug resistant infections are severe. The recommendation of priority review by CDE for cefepime-taniborbacta...

September 20, 2023 | News

Stay Connected